Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
Why the study?
Does 2-dimensional speckle tracking echocardiography predict early subclinical cardiotoxicity in breast cancer patients receiving anthracycline-trastuzumab chemotherapy?
Population
66 patients with breast cancer receiving anthracycline-trastuzumab treatment, mean age 52 years, normal…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Early GLS monitoring may flag cardiotoxicity risk during anthracycline-trastuzumab therapy; leaves open prospective validation before routine adoption.
Structured PICO
Does 2-dimensional speckle tracking echocardiography predict early subclinical cardiotoxicity in breast cancer patients receiving anthracycline-trastuzumab chemotherapy?
P
Population
66 patients with breast cancer receiving anthracycline-trastuzumab treatment, mean age 52 years, normal pretreatment LVEF.
I
Intervention
2-dimensional speckle tracking echocardiography (2D-STE) at pretreatment, first cycle, and second cycle of chemotherapy
O
Outcome
Cardiotoxicity, defined as a decrease in LVEF of at least 10 percentage points from baseline on follow-up echocardiographysurrogate
Early changes in global longitudinal strain measured by 2D speckle tracking echocardiography after one cycle of anthracycline-trastuzumab chemotherapy strongly predict subsequent cardiotoxicity in breast cancer patients.
Cite This Study
Calle et al. (2018) studied this question.